An interventional study of Thalidomide and Argon Plasma Coagulation in Liver Cirrhosis and Gastric Antral Vascular Ectasia, sponsored by Institute of Liver and Biliary Sciences, India. Not yet recruiting at 1 site in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-13.
Sponsored by Institute of Liver and Biliary Sciences, India · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India — 15 open to participants now, 15 under way, 1 of them phase 3. Liver Cirrhosis · Institute of Liver and Biliary Sciences, India.
Among the 53 studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India, this one is the 17th largest by planned enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2025, is one of 40 with no phase, reaches primary completion later than 9 of the 14 other live ones, and was the 47th registered.
1,302 studies on the registry are indexed under Liver Cirrhosis; 340 are open to participants now.
Browse Liver Cirrhosis studies →15 of the 53 studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India are open now, in 1 country. Recruiting first, the newest first:
Institute of Liver and Biliary Sciences, India · Sites in India
Ages 18–75
Institute of Liver and Biliary Sciences, India · Sites in India
Ages 18–70
Institute of Liver and Biliary Sciences, India · Sites in India
Ages 18–70
Institute of Liver and Biliary Sciences, India · Sites in India
Ages 18–80
Institute of Liver and Biliary Sciences, India · Sites in India
Ages 18–75
By country, each count listing its studies:
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 100 across the 42 interventional studies, 56 across the 11 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institute of Liver and Biliary Sciences, India is the lead sponsor of 303 studies on the registry; 88 are open to participants now.
3 of the studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07002827Institute of Liver and Biliary Sciences, IndiaEffect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis. | 2026-12-30 |
| NCT07433881Institute of Liver and Biliary Sciences, IndiaSerosurvey of HAV Immunity and Single-dose Vaccine Immunogenicity Among Patients With Cirrhosis | 2027-02-27 |
| NCT07465471Institute of Liver and Biliary Sciences, IndiaCarvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis. | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 53 studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Gastric Antral Vascular Ectasia (GAVE) is an erosive form of gastritis distinguished by veno-capillary ectasia, which manifests as tortuous columns of dilated vessels. Histologically, these vessels show dilated mucosal capillaries filled with fibrin thrombi, accompanied by fibromuscular hyperplasia and spindle cell proliferation of the lamina propria. GAVE is prevalent in about 12% of patients with cirrhosis, with 60-70% of these patients becoming transfusion-dependent due to severe anaemia caused by GAVE related bleeding. The most commonly used treatment for GAVE is endoscopic therapy using Argon Plasma Coagulation (APC), which, while effective, often requires multiple sessions due to a high recurrence rate of 30-60%. These frequent interventions increase the burden on patients and healthcare systems. As a result, alternative treatments have been sought. Thalidomide, known for its potent antiangiogenic properties, significantly lowers vascular endothelial growth factor (VEGF) levels, offering a promising non-invasive treatment option. Early studies, such as those by García-Pagán have demonstrated thalidomide's effectiveness in reducing transfusion requirements and managing bleeding in cirrhotic patients with GAVE, yet its comprehensive efficacy and safety profile remains under-studied. This project aims to rigorously evaluate the efficacy and safety of thalidomide compared to APC in managing GAVE-related anemia in cirrhotic patients. Through a controlled trial, this study will provide vital data to potentially shift treatment paradigms, enhance patient quality of life, and reduce the need for repetitive invasive procedures.
Aim: To evaluate and compare the efficacy and safety of thalidomide with argon plasma coagulation (APC) in managing gastric antral vascular ectasia (GAVE)-related anaemia in patients with cirrhosis.
Hypothesis: Thalidomide, due to its antiangiogenic effects, will more effectively reduce GAVE-related bleeding, improve haemoglobin levels, and decrease transfusion dependency compared to APC in patients with cirrhosis and GAVE-related anaemia.
Study Design:
Single-centre, open-label, randomised controlled trial to compare the efficacy and safety of thalidomide versus argon plasma coagulation (APC) in managing GAVE-related anaemia in cirrhotic patients.
Study Population:
Adult patients (aged 18-65 years) diagnosed with cirrhosis and endoscopically confirmed GAVE-related anaemia, presenting at the Institute of Liver and Biliary Sciences.
Randomization: Patients will be randomly assigned to receive either thalidomide or APC in a 1:1 ratio by block randomization method with block size of 10 and it will be implemented by using ILBS IWRS facility.
Follow-up and Assessments:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Endoscopically confirmed diagnosis of GAVE
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive oral thalidomide starting at 50 mg daily, with a weekly increase of 50 mg up to a maximum of 200 mg daily, continued for four months.
Drug: Thalidomide
Patients will undergo APC treatment every 2-3 weeks initially, followed by maintenance sessions every three months as required.
Procedure: Argon Plasma Coagulation
Patients will receive oral thalidomide starting at 50 mg daily, with a weekly increase of 50 mg up to a maximum of 200 mg daily, continued for four months
Patients will undergo APC treatment every 2-3 weeks initially, followed by maintenance sessions every three months as required.
Mean increase in hemoglobin levels from baseline
Time frame: 4 months
Atleast 50 percent change in requirement of PRBCs transfusions at the end of 4 months
Time frame: 4 months
Increase in serum iron levels, percent transferrin saturation at the end of 4months
Time frame: 4 months
Change in amount of PRBC's transfused at the end of 4 months.
Time frame: 4 months
Change in GAVE related bleeding episodes at the end of 4 months
Time frame: 4 months
Number of hospitalizations due to GAVE related anemia, in 4 months
Time frame: 4 months
Duration of days of hospitalization due to GAVE related anemia in 4 months
Time frame: 4 months
Need of rescue endoscopic sessions in 4 months in thalidomide group
Time frame: 4 months
Endoscopic resolution of GAVE at the end of 4 months
Endoscopic resolution is defined as endoscopic findings of GAVE as absent.
Time frame: 4 months
Change in VEGF levels in Thalidomide group at the end of 4 months
Time frame: 4 months
Change in pepsinogen levels in Thalidomide group at the end of 4 months
Time frame: 4 months
Change in gastrin levels in Thalidomide group at the end of 4 months
Time frame: 4 months
Adverse events in each group at the end of 4 months
Time frame: 4 months
Quality of life measures - Short Form 36
Quality of life measures - Short Form 36 ranges from 0 to 100, 0 indicate maximum disability and 100 indicate no disability.
Time frame: 4 months
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jan 2025; primary completion for Jan 2026, 12 months later.
Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 12 months is below that.
Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Thalidomide
Institute of Liver and Biliary Sciences, India →